文献速递类风湿关节炎

SM03(抗人CD22单克隆抗体)治疗活动性类风湿关节炎的II期随机双盲安慰剂对照研究

SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

主要终点24周ACR20应答率在高剂量组(65.3%,P=0.002)和低剂量组(56.9%,P=0.024)均显著高于安慰剂组(34.0%),两剂量组间相当。不良事件率三组无统计学差异,SM03耐受性良好。

要点

  • 高、低剂量SM03的24周ACR20应答率均显著优于安慰剂。
  • 高剂量与低剂量SM03的ACR20应答率组间无显著差异。
  • SM03治疗期间不良事件率与安慰剂组无统计学差异。

核心结论

  • 在背景MTX治疗的中国活动性RA患者中,SM03累积2400 mg和3600 mg在24周内均有效且耐受性良好。

研究设计与样本

  • 患者按1:1:1随机接受高剂量SM03(累积3600 mg,600 mg×6次输注,第0、2、4、12、14、16周)、低剂量SM03(累积2400 mg,600 mg×4次输注,第0、2、12、14周)或安慰剂。
  • 主要终点为24周ACR20应答率,同时评估安全性。

主要发现

  • 24周ACR20应答率:高剂量组65.3%(P=0.002)、低剂量组56.9%(P=0.024)、安慰剂组34.0%。
  • 高剂量组与低剂量组ACR20应答率相当。
  • 不良事件率:高剂量组35.3%、低剂量组51.9%、安慰剂组34.6%,组间无统计学差异。
  • 无患者报告严重治疗中出现感染或恶性肿瘤。

临床怎么用

  • 对于接受背景MTX的活动性RA患者,可考虑SM03累积2400 mg或3600 mg方案,两者24周疗效均优于安慰剂且安全性可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: SM03, a novel chimaeric mAb specific to B cell-restricted antigen CD22, has been developed to treat RA and other B-cell-related diseases. This 24-week phase II randomized, double-blind, multi-dose, placebo-controlled study aimed to evaluate the efficacy and safety of SM03 in moderately-to-severely active RA patients in China. METHODS: One hundred and fifty-six patients on background MTX were randomized in a 1:1:1 ratio to receive a cumulative dose of 3600 mg (high dose, 600 mg × 6 infusions at weeks 0, 2, 4, 12, 14 and 16) or 2400 mg SM03 (low dose, 600 mg × 4 infusions at weeks 0, 2, 12 and 14) or the placebo. The primary outcome was the 24-week ACR 20% improvement criteria (ACR20) response rate. Safety was also assessed. RESULTS: The 24-week ACR20 response rate was significantly higher with high- (65.3%, P = 0.002) and low-dose SM03 (56.9%, P = 0.024) than with placebo (34.0%), but comparable between the high- and low-dose group. The rate of adverse events was not statistically different among the high-dose group (35.3%), the low-dose group (51.9%) and the placebo group (34.6%). Thirteen (12.6%) patients receiving SM03 reported treatment-emergent infections, including 3.9% patients in the high-dose group. No patients reported severe treatment-emergent infections or malignancies. CONCLUSIONS: In active RA Chinese patients receiving background MTX, SM03 at a cumulative dose of both 2400 mg and 3600 mg is efficacious and well-tolerated throughout the 24 weeks of treatment. Moreover, SM03 has demonstrated a good safety profile. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT04192617.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Li J, Li M, Wu D, et al. SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022. PMID: 34508557. doi:10.1093/rheumatology/keab699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。